Volume 2 / Issue 1
This past December, Genomic Health marked the 10th anniversary of the first Oncotype DX data presentation at the San Antonio Breast Cancer Symposium! The Oncotype DX Breast Cancer Assay continues to be at the forefront as the most validated, utilized and studied genomic assay for breast cancer.
The Annual San Antonio Breast Cancer Conference is an event that highlights medical and scientific advances in breast cancer. With that in mind, we at Genomic Health wanted to take this opportunity and feature several items of interest from the conference in this issue of our quarterly newsletter.
<strong>Spotlight On... Dr. Lee Schwartzberg</strong>
<strong>Does Accurate Assessment of HR Status Require Dual Testing?</strong>
<strong>Direct Comparison of Three Breast Cancer Stratification Assays</strong>
<strong>WSG-ADAPT HR+/HER2- Trial Run-In Phase Presented at SABCS</strong>
<strong>A Surgeon’s Perspective on Genomic Assays for Breast Cancer</strong>
<strong>How a Surgeon Utilizes Genomic Assays for Breast Cancer</strong>
Dr. Schwartzberg, MD, FACP, President and Chief Medical Director at the West Clinic in Memphis, Tennessee shares his thoughts on the impact of the Oncotype DX Breast Cancer Assay on the treatment of early-stage breast cancer.
Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?
Copyright © 2004-2017 Genomic Health, Inc. All Rights Reserved.
The content on this site is intended for U.S. patients and caregivers only.